Home › Sindromi mielodisplastiche › Ohio › Columbus
Studi clinici su Sindromi mielodisplastiche a Columbus, OH
14 studi su Sindromi mielodisplastiche cercano partecipanti presso sedi a Columbus e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
In reclutamentoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
In reclutamentoFase 2
- Ohio State University Comprehensive Cancer Center, Columbus
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
In reclutamentoFase 1/2
- The Ohio State University, Columbus
Collection of Tissue Samples for Cancer Research
In reclutamentoStudio osservazionale
- Ohio State University, Columbus
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
In reclutamentoFase 1
- Ohio State University, The James Comprehensive Cancer, Columbus
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
In reclutamentoFase 3
- Ohio State University Comprehensive Cancer Center, Columbus
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
In reclutamentoFase 1/2
- Nationwide Children's Hospital, Columbus
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
In reclutamentoFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
In reclutamentoFase 2/3
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
In reclutamentoFase 1
- Ohio State University Medical Center, Columbus
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
In reclutamentoFase 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Columbus
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
In reclutamentoFase 1
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
HPC Offered for PRESERVE Expansion
In reclutamentoStudio osservazionale
- The Ohio State University Medical Center, Columbus
Studi su Sindromi mielodisplastiche in altre città
- Houston, TX43 studi
- Baldwin Park, CA26 studi
- New York City, NY21 studi
- Seattle, WA21 studi
- Washington, DC20 studi
- Boston, MA19 studi
- Tampa, FL19 studi
- Miami, FL17 studi
- Durham, NC14 studi
- Chicago, IL13 studi
- Atlanta, GA13 studi
- St. Louis, MO13 studi
Altri studi a Columbus
- Cancro del polmone non a piccole cellule56 studi
- Cancro al seno39 studi
- Cancro ovarico39 studi
- Cancro (tutti i tipi)38 studi
- Cancro ai polmoni37 studi
- Leucemia mieloide acuta35 studi
- Leucemia linfatica cronica28 studi
- Cancro metastatico27 studi
- Cancro dell'endometrio25 studi
- Cancro colorettale24 studi
- Cancro alla prostata24 studi
- Mieloma multiplo24 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.